Enasidenib (AG-221), a selective oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, in patients with myelodysplastic syndromes (MDS) Meeting Abstract
| Authors: | Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; Tosolini, A.; Xu, Q.; Amatangelo, M.; Gupta, I.; Knight, R. D.; de Botton, S.; Tallman, M. S.; Kantarjian, H. M. |
| Abstract Title: | Enasidenib (AG-221), a selective oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, in patients with myelodysplastic syndromes (MDS) |
| Meeting Title: | 14th International Symposium on Myelodysplastic Syndromes (MDS) |
| Journal Title: | Leukemia Research |
| Volume: | 55 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 May 3-6 |
| Meeting Location: | Valencia, Spain |
| ISSN: | 0145-2126 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2017-04-01 |
| Start Page: | S24 |
| End Page: | S25 |
| Language: | English |
| ACCESSION: | WOS:000417653300039 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0145-2126(17)30151-0 |
| Notes: | Meeting Abstract: 38 -- 14th International Symposium on Myelodysplastic Syndromes (MDS) -- MAY 03-06, 2017 -- Valencia, SPAIN -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work